Tags

Type your tag names separated by a space and hit enter

Midodrine. A review of its therapeutic use in the management of orthostatic hypotension.
Drugs Aging. 1998 Jan; 12(1):76-86.DA

Abstract

Midodrine is a prodrug which undergoes enzymatic hydrolysis to the selective alpha 1-adrenoceptor agonist desglymidodrine after oral administration. Oral midodrine significantly increases 1-minute standing systolic blood pressure compared with placebo. The drug also improves standing time and energy level and clinical symptoms of orthostatic hypotension including dizziness, light-headedness and syncope. Comparative studies have shown midodrine to have similar efficacy to dihydroergotamine mesylate, norfenefrine, fludrocortisone and etilefrine, and to be more effective than dimetofrine and ephedrine in patients with orthostatic hypotension. Midodrine is well tolerated, with the most commonly reported adverse events being piloerection, pruritus, paraesthesias, urinary retention and chills. The risk of supine hypertension, which is associated with midodrine therapy in up to 25% of patients, can be reduced by taking the final daily dose at least 4 hours before bedtime. Thus, oral midodrine is an effective therapeutic option for the management of various forms of orthostatic hypotension. This well-tolerated agent is likely to be useful in conjunction with standard nonpharmacological care.

Authors+Show Affiliations

Adis International Limited, Auckland, New Zealand. demail@adis.co.nzNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

9467688

Citation

McClellan, K J., et al. "Midodrine. a Review of Its Therapeutic Use in the Management of Orthostatic Hypotension." Drugs & Aging, vol. 12, no. 1, 1998, pp. 76-86.
McClellan KJ, Wiseman LR, Wilde MI. Midodrine. A review of its therapeutic use in the management of orthostatic hypotension. Drugs Aging. 1998;12(1):76-86.
McClellan, K. J., Wiseman, L. R., & Wilde, M. I. (1998). Midodrine. A review of its therapeutic use in the management of orthostatic hypotension. Drugs & Aging, 12(1), 76-86.
McClellan KJ, Wiseman LR, Wilde MI. Midodrine. a Review of Its Therapeutic Use in the Management of Orthostatic Hypotension. Drugs Aging. 1998;12(1):76-86. PubMed PMID: 9467688.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Midodrine. A review of its therapeutic use in the management of orthostatic hypotension. AU - McClellan,K J, AU - Wiseman,L R, AU - Wilde,M I, PY - 1998/2/19/pubmed PY - 1998/2/19/medline PY - 1998/2/19/entrez SP - 76 EP - 86 JF - Drugs & aging JO - Drugs Aging VL - 12 IS - 1 N2 - Midodrine is a prodrug which undergoes enzymatic hydrolysis to the selective alpha 1-adrenoceptor agonist desglymidodrine after oral administration. Oral midodrine significantly increases 1-minute standing systolic blood pressure compared with placebo. The drug also improves standing time and energy level and clinical symptoms of orthostatic hypotension including dizziness, light-headedness and syncope. Comparative studies have shown midodrine to have similar efficacy to dihydroergotamine mesylate, norfenefrine, fludrocortisone and etilefrine, and to be more effective than dimetofrine and ephedrine in patients with orthostatic hypotension. Midodrine is well tolerated, with the most commonly reported adverse events being piloerection, pruritus, paraesthesias, urinary retention and chills. The risk of supine hypertension, which is associated with midodrine therapy in up to 25% of patients, can be reduced by taking the final daily dose at least 4 hours before bedtime. Thus, oral midodrine is an effective therapeutic option for the management of various forms of orthostatic hypotension. This well-tolerated agent is likely to be useful in conjunction with standard nonpharmacological care. SN - 1170-229X UR - https://www.unboundmedicine.com/medline/citation/9467688/Midodrine__A_review_of_its_therapeutic_use_in_the_management_of_orthostatic_hypotension_ L2 - https://dx.doi.org/10.2165/00002512-199812010-00007 DB - PRIME DP - Unbound Medicine ER -